AADI BIOSCIENCES DL-0001
Whitehawk Therapeutics, Inc., an oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides a three-asset antibody-drug conjugate (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in March 2025. Whitehawk Therapeutics, Inc. was incorporated in 200… Read more
AADI BIOSCIENCES DL-0001 (3350) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, AADI BIOSCIENCES DL-0001 (3350) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
AADI BIOSCIENCES DL-0001 - Net Assets Trend (None–None)
This chart illustrates how AADI BIOSCIENCES DL-0001's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AADI BIOSCIENCES DL-0001 (None–None)
The table below shows the annual net assets of AADI BIOSCIENCES DL-0001 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to AADI BIOSCIENCES DL-0001's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
AADI BIOSCIENCES DL-0001 Competitors by Market Cap
The table below lists competitors of AADI BIOSCIENCES DL-0001 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Taurus Armas S.A
SA:TASA3
|
$63.88 Million |
|
Berner Industrier B
ST:BERNER-B
|
$63.88 Million |
|
Imperium Group Global Holdings Limited
PINK:IPGGF
|
$63.89 Million |
|
WRKR Ltd
AU:WRK
|
$63.90 Million |
|
Micro Systemation AB (publ)
ST:MSAB-B
|
$63.85 Million |
|
San Lien Technology
TWO:5493
|
$63.84 Million |
|
FLITTO Inc
KQ:300080
|
$63.84 Million |
|
Biosyent Inc.
PINK:BIOYF
|
$63.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AADI BIOSCIENCES DL-0001's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares AADI BIOSCIENCES DL-0001's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently AADI BIOSCIENCES DL-0001 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares AADI BIOSCIENCES DL-0001's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AADI BIOSCIENCES DL-0001 (3350) | €- | N/A | N/A | $63.87 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |